Galderma Group AG
Restylane Defyne in a Stepwise Treatment Approach
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 62
- Registration Number
- NCT04520997
- Locations
- 🇮🇹
Galderma Research Site, Palermo, Italy
Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 286
- Registration Number
- NCT04501666
- Locations
- 🇬🇧
Galderma Investigational Site, Newcastle Upon Tyne, United Kingdom
A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 274
- Registration Number
- NCT04501679
- Locations
- 🇨🇭
Galderma Investigational Site, Weinfelden, Switzerland
A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)
- Conditions
- Interventions
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 202
- Registration Number
- NCT04451330
- Locations
- 🇵🇷
Galderma Investigational Site, Aibonito, Puerto Rico
A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 225
- Registration Number
- NCT04365387
- Locations
- 🇺🇸
Galderma Investigational Site (Site#8813), Los Angeles, California, United States
🇺🇸Galderma Investigational Site (Site#8786), Clearwater, Florida, United States
🇺🇸Galderma Investigational Site (Site#8792), Doral, Florida, United States
A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 125
- Registration Number
- NCT04269395
- Locations
- 🇺🇸
Galderma Investigational Site (Site#8447), Fort Smith, Arkansas, United States
🇺🇸Galderma Investigational Site (Site#8636), Fountain Valley, California, United States
🇺🇸Galderma Investigational Site (Site#8734), Pembroke Pines, Florida, United States
Treatment of Moderate to Severe Glabellar Lines
- Conditions
- Interventions
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 300
- Registration Number
- NCT04249583
- Locations
- 🇺🇸
Dallas Center for Dermatology & Aesthetics, Dallas, Texas, United States
🇺🇸Integrated Aesthetics, Inc, Spring, Texas, United States
🇺🇸Sachin M Shridharani, MD, New York, New York, United States
Treatment of Moderate to Severe Lateral Canthal Lines
- Conditions
- Interventions
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 303
- Registration Number
- NCT04249687
- Locations
- 🇺🇸
Facial Plastic Surgicenter, Ltd, Baltimore, Maryland, United States
🇺🇸Siperstein Dermatology Group, PLLC, Boynton Beach, Florida, United States
🇺🇸Dermatology Cosmetic Laser Medical Associates, San Diego, California, United States
Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination
- Conditions
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 413
- Registration Number
- NCT04247074
- Locations
- 🇺🇸
Ava MD, Santa Monica, California, United States
🇺🇸Baumann Cosmetic & Research Institute, Inc, Miami, Florida, United States
🇺🇸Clinical Testing of Beverly Hills, Encino, California, United States
Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
- Conditions
- Interventions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 902
- Registration Number
- NCT04225260
- Locations
- 🇺🇸
Skin Laser and Surgery Specialist of NY/NJ, Hackensack, New Jersey, United States
🇺🇸Center for Clinical and Cosmetic Research, Aventura, Florida, United States
🇺🇸Steven Fagien, MD, PA, Boca Raton, Florida, United States